Evercore ISI raised the firm’s price target on Editas Medicine (EDIT) to $15 from $13 and keeps an Outperform rating on the shares. The firm updated models among its small-to-mid cap biotech coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- USPTO Ruling Impacts Editas Medicine CRISPR IP Position
- Editas Medicine announces USPTO reaffirms prior decision on CRISPR/Cas9 patents
- Regulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects
- Editas Medicine upgraded to Buy from Hold at JonesResearch
- Editas Medicine reports Q4 EPS (6c), consensus (26c)